Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H19NO2S.C4H4O4 |
| Molecular Weight | 405.465 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.C(OC1=C(CC2=CC=CS2)C=CC=C1)C3CNCCO3
InChI
InChIKey=ONQAJVWRFPPADI-BTJKTKAUSA-N
InChI=1S/C16H19NO2S.C4H4O4/c1-2-6-16(19-12-14-11-17-7-8-18-14)13(4-1)10-15-5-3-9-20-15;5-3(6)1-2-4(7)8/h1-6,9,14,17H,7-8,10-12H2;1-2H,(H,5,6)(H,7,8)/b;2-1-
| Molecular Formula | C16H19NO2S |
| Molecular Weight | 289.393 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | C4H4O4 |
| Molecular Weight | 116.0722 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Teniloxazine (also known as sulfoxazine or sufoxazine or Y 8894) was developed as an antidepressant. Teniloxazine belongs to the selective norepinephrine reuptake inhibitors (NRIs) and was studied for the treatment of the major depressive disorder. Clinical trials have shown that 50 mg of the drug lacked the anticholinergic, sedative and cardiovascular effects. In the elderly, some effects were recognized, in part, due to pharmacokinetic alteration. In addition, teniloxazine was studied for patients with Alzheimer's disease, however, doesn’t exist any development report for this study.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Pharmacological studies on sufoxazine (Y-8894). (I) Effects on experimental amnesia in mice]. | 1985 Feb |
|
| [Pharmacological studies on sufoxazine (Y-8894). (II). Anti-anoxic effect]. | 1985 Oct |
|
| [Pharmacological studies on Y-8894. (IV). Ameliorative effect on a cerebral energy metabolism disorder induced by KCN]. | 1986 Nov |
|
| [Pharmacological studies on Y-8894. (III). Its effect on the abnormal electrocorticogram induced by destruction of the internal capsule]. | 1986 Oct |
|
| The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. | 2019 Jun |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:55:48 GMT 2023
by
admin
on
Sat Dec 16 07:55:48 GMT 2023
|
| Record UNII |
1BY0CJ6QWX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6438129
Created by
admin on Sat Dec 16 07:55:49 GMT 2023 , Edited by admin on Sat Dec 16 07:55:49 GMT 2023
|
PRIMARY | |||
|
62473-80-7
Created by
admin on Sat Dec 16 07:55:49 GMT 2023 , Edited by admin on Sat Dec 16 07:55:49 GMT 2023
|
PRIMARY | |||
|
1BY0CJ6QWX
Created by
admin on Sat Dec 16 07:55:49 GMT 2023 , Edited by admin on Sat Dec 16 07:55:49 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |